Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alexza Pharmaceuticals, Inc.

http://www.alexza.com

Latest From Alexza Pharmaceuticals, Inc.

Keeping Track: TGT’s Ukoniq Is Latest PI3K Inhibitor To Fall; GSK’s Daprodustat, Aeglea’s Pegzilarginase Headline Submissions

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.

Tech Transfer Round-Up Deals

BioXcel Gets First Approval With Igalmi For Neuropsychiatric Agitation

Sublingual film product Igalmi is approved to treat agitation related to schizophrenia and bipolar disorder, but BioXcel also is targeting a bigger market opportunity in Alzheimer’s dementia.

Approvals Business Strategies

Are Investors ‘Skeptical’ Of Fresenius Kabi’s €495m mAbxience Acquisition?

Fresenius Kabi’s proposed agreement to acquire a majority 55% stake in biosimilars firm mAbxience has been put under the microscope by one analyst, amid setbacks that have stymied the return on investment for Kabi’s nascent biosimilars unit.

Biosimilars Strategy
See All

Company Information

  • Other Names / Subsidiaries
    • Addicere Therapeutics, Inc.
UsernamePublicRestriction

Register